2-Diphenylphosphoryloxyethyl(trimethyl)azanium;iodide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Diphenylphosphoryloxyethyl(trimethyl)azanium;iodide
• 化学式: C17H23INO2P
• 分子量: 431.25
• InChiKey: MVKIEQGWDHAQBP-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.36
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• USE OF COPPER AND GLUTAMATE IN CELL CULTURE FOR PRODUCTION OF POLYPEPTIDES
  申请人：Wyeth LLC

  公开号：EP2924113A1

  公开（公告）日：2015-09-30

  An improved system for large scale production of polypeptides in cell culture is provided. In accordance with the present invention, cells expressing a polypeptide of interest are grown in media that contain copper, glutamate or both. The use of such a system allows production of polypeptides in which misfolding and/or aggregation are reduced, and in which total glycosylation is increased. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, agricultural or other commercial compositions.

  本发明提供了一种在细胞培养中大规模生产多肽的改进系统。根据本发明，表达相关多肽的细胞在含有铜、谷氨酸或两者的培养基中生长。使用这种系统可以生产出减少错误折叠和/或聚集、增加总糖基化的多肽。根据本发明表达的多肽可以很好地用于制备药物、农用或其他商业组合物。
• Epicardial-derived paracrine factors for repairing cardiac tissue
  申请人：Regencor, Inc.

  公开号：US10682416B2

  公开（公告）日：2020-06-16

  Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors (such as, hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as methods for using the same.

  本文特别提供了包含心外膜衍生的旁分泌因子（如低聚糖化的类软骨素 1 (FSTL1)）的组合物和试剂盒，用于治疗和修复由心血管疾病、心肌梗塞（MI）、其他缺血性事件或心脏生长缺陷引起的心脏组织损伤，以及使用这些组合物和试剂盒的方法。
• GLYCOLYSIS-INHIBITING SUBSTANCES IN CELL CULTURE
  申请人：Wyeth

  公开号：EP2064315A2

  公开（公告）日：2009-06-03
• USE OF COPPER AND GLUTAMATE IN CELL CULTURE FOR PRODUCTION OF POLYPEPTIDES
  申请人：Wyeth

  公开号：EP2115126A1

  公开（公告）日：2009-11-11
• CONTROL OF PROTEIN GLYCOSYLATION AND COMPOSITIONS AND METHODS RELATING THERETO
  申请人：Pfizer Inc.

  公开号：EP2421892A1

  公开（公告）日：2012-02-29